| __timestamp | Merus N.V. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 7751000 |
| Thursday, January 1, 2015 | 839656 | 10251000 |
| Friday, January 1, 2016 | 4478145 | 9575000 |
| Sunday, January 1, 2017 | 16432324 | 10912000 |
| Monday, January 1, 2018 | 11890871 | 11049000 |
| Tuesday, January 1, 2019 | 34110000 | 11646000 |
| Wednesday, January 1, 2020 | 35781000 | 13265000 |
| Friday, January 1, 2021 | 40896000 | 25805000 |
| Saturday, January 1, 2022 | 52200000 | 35182000 |
| Sunday, January 1, 2023 | 59836000 | 94999000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Merus N.V. and Viridian Therapeutics, Inc. have been navigating this financial landscape since 2014. Over the past decade, Merus N.V. has seen a steady increase in SG&A expenses, peaking at nearly 60 million in 2023, a 15-fold increase from 2014. In contrast, Viridian Therapeutics, Inc. experienced a more volatile trajectory, with a dramatic surge in 2023, reaching approximately 95 million, a staggering 12-fold rise from its 2014 figures. This data highlights the contrasting strategies of these companies in managing operational costs. While Merus N.V. has shown consistent growth, Viridian's recent spike suggests a strategic pivot or expansion. Understanding these trends offers valuable insights into their financial health and strategic priorities.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Merus N.V.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Merus N.V.
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Rhythm Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Veracyte, Inc. vs Merus N.V.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Merus N.V. or Galapagos NV
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.